17,261 trials
SARS-CoV-2 Infection
Primary: Change From Baseline in Logarithm Base 10 (Log10) Transformed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribo Nucleic Acid (RNA) Level on Day 5…
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Primary: Correlation of Tumor-informed CAPP-Seq ctDNA Analysis With Radiologic Tumor Assessments — 100; 66; 100; NA Percent Accuracy
Cardiac Rehabilitation
Primary: Cardiac Rehabilitation Attendance — 16.9; 12.0; 24.1; 10.9 sessions of CR
Breast Cancer · Breast Carcinoma · Breast Tumors
Primary: Time to Disease Progression - Tumor Response Based on RECIST 1.1 Criteria — 7.1; 10.2; 5.7; 9.6 months
Hidradenitis Suppurativa
Primary: Percent Change From Baseline in Total Abscess and Inflammatory Nodule Count at Week 12 — -34.7; -38.8 percent change
Urological System Complication of Procedure · Urinary Tract Infections
Primary: The Main Outcome Measure Was the Incidence of Urinary Tract Infection (UTI) Post-urodynamic Study (UDS), Diagnosed Through Urinalysis Indicating Leukocyturia, Positive…
Scleroderma, Systemic
Primary: Main Study: Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24 — -9.5; 3.1 Score on a scale — p=< 0.001
Advanced Melanoma
Primary: Objective Response Rate (ORR) — 21.4 Percentage of Participants
Non-Segmental Vitiligo
Primary: Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 — -14.36; -21.96; -35.63; -33.96 Percent change from baseline — p=0.304
Chronic Kidney Diseases · Cognitive Decline
Primary: Change in Vascular Endothelial Function at 12 Months — -0.1; -0.7 %change
Metastatic Melanoma · Stage IV Cutaneous Melanoma AJCC v6 and v7
Primary: CTL With Anti-CTLA4
PTSD
Primary: CAPS-5 — 41.6; 20.8 score on a scale
Sickle Cell Disease
Primary: Percentage of Group C Participants Who Achieved Complete Resolution of Vaso-occlusive Events (VOE-CR) — 87.5 percentage of participants
Thymic Carcinoma · Non-small Cell Lung Cancer · Refractory Thoracic Tumors
Primary: Recommended Phase II Combination Dose in Phase I (Per Common Terminology Criteria for Adverse Events (CTCAE) Criteria Version 5) — 200 mg
Hepatocellular Carcinoma · Hepatoma · Liver Cancer, Adult
Primary: Objective Response Rate(ORR) Assessed by BICR — 13.3; 10.5; 12.5 Percentage